Owing to the vast target repertoire of RUNX1 and STAT3, both of them were reported to be critical for CML progression towards BC phase and development of imatinib resistance [26, 27], presenting physiologically challenging scenarios for CML treatment [2, 28, 29]. Here, STAT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.